Similar articles

• Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

  Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S, Cameron D. Geyer CE, et al. N Engl J Med. 2006 Dec 28;355(26):2733-43. doi: 10.1056/NEJMoa064320. N Engl J Med. 2006. PMID: 17192538 Clinical Trial.
• Lapatinib plus capecitabine in breast cancer.

  Sonpavde G. Sonpavde G. N Engl J Med. 2007 Apr 5;356(14):1471; author reply 1471-2. doi: 10.1056/NEJMc070182. N Engl J Med. 2007. PMID: 17409332 No abstract available.
• Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer.

  Gajria D, Gonzalez J, Feigin K, Patil S, Chen C, Theodoulou M, Drullinsky P, D'Andrea G, Lake D, Norton L, Hudis CA, Traina TA. Gajria D, et al. Breast Cancer Res Treat. 2012 Jan;131(1):111-6. doi: 10.1007/s10549-011-1749-y. Epub 2011 Sep 4. Breast Cancer Res Treat. 2012. PMID: 21898114 Clinical Trial.
• Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer.

  Cameron DA, Stein S. Cameron DA, et al. Nat Clin Pract Oncol. 2008 Sep;5(9):512-20. doi: 10.1038/ncponc1156. Epub 2008 Jul 1. Nat Clin Pract Oncol. 2008. PMID: 18594499 Review.
• [Recent advances in targeted therapies in the treatment of HER2-positive metastatic breast cancer].

  Ismaili N, Belbaraka R, Elomrani A, Khouchani M, Tahri A. Ismaili N, et al. Presse Med. 2013 Nov;42(11):1461-8. doi: 10.1016/j.lpm.2013.01.066. Epub 2013 May 27. Presse Med. 2013. PMID: 23721860 Review. French.